Earnings ·
Reports Q3 net loss of $11.5M, or $0.38 per share, as cash reserves stand at $124.7 million
RNACCartesian Therapeutics, Inc.
Cartesian Therapeutics reported a third-quarter 2026 net loss of $11.5 million, or $0.38 per share, compared to a $35.9 million loss in the prior-year period. The improvement was driven by a $46.1 million gain on the change in fair value of contingent value rights liability and lower operating losses relative to revenue declines. Cash, cash equivalents, and restricted cash totaled $124.7 million as of September 30, 2026, providing runway into 2028. The company highlighted that Phase 3 AURORA trial data for Descartes-08 in myasthenia gravis is expected in the first quarter of 2027, with a biologics license application planned for mid-2027. Cartesian Therapeutics operates as a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases.